AEON · Insider Trading
AEON Biopharma, Inc.
Every open-market purchase and sale reported by AEON officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-21 | Timothy P Lynch | 10%+ Owner | Buy | +1,150,000 | +$243.46K |
| 2026-06-22 | Shelley B Thunen | Director | A | +222,684 | — |
| 2026-06-22 | Jost Fischer | Director | A | +222,684 | — |
| 2026-06-22 | Robert J Palmisano | Director | A | +222,684 | — |
| 2026-06-22 | Marc Forth | Director | A | +222,684 | — |
| 2026-06-22 | Eric G Carter | Director | A | +222,684 | — |
| 2026-04-03 | John Bencich | CHIEF FINANCIAL OFFICER | A | +754,717 | — |
| 2026-03-11 | Chad Oh | CHIEF MEDICAL OFFICER | A | +2,179,372 | — |
| 2026-03-05 | Alexander Blair Wilson | CLO, CSO, and Corp Secretary | A | +2,179,372 | — |
| 2026-03-05 | Jennifer Sy | PRINCIPAL ACCOUNTING OFFICER | A | +1,500,925 | — |
| 2026-02-19 | Robert E. Bancroft | PRESIDENT & CEO | A | +3,000,000 | — |
| 2025-05-23 | Robert J Palmisano | Director | A | +308,641 deriv. | — |
| 2025-05-23 | Jost Fischer | Director | Buy | +60,000 | +$29.25K |
| 2025-05-23 | Marc Forth | Director | A | +370,370 deriv. | — |
| 2025-05-23 | Shelley B Thunen | Director | A | +308,641 deriv. | — |
| 2025-05-23 | Alexander Blair Wilson | Exec VP, CLO & Corp Secretary | A | +1,316,872 deriv. | — |
| 2025-05-23 | Eric G Carter | Director | A | +308,641 deriv. | — |
| 2025-05-23 | Jost Fischer | Director | A | +308,641 deriv. | — |
| 2025-05-23 | Jennifer Sy | Chief Accounting Officer | A | +925,925 deriv. | — |
| 2025-05-23 | Chad Oh | Chief Medical Officer | A | +1,316,872 deriv. | — |
| 2025-05-21 | Jost Fischer | Director | Buy | +110,000 | +$55.30K |
| 2025-05-16 | Robert E. Bancroft | President & CEO | A | +177,103 | — |
| 2025-05-01 | Robert E. Bancroft | President & CEO | A | +59,034 deriv. | — |
| 2024-09-10 | Robert J Palmisano | Director | A | +36,021 | — |
| 2024-09-04 | Shelley B Thunen | Director | A | +36,021 | — |
| 2024-09-04 | Jost Fischer | Director | A | +36,021 | — |
| 2024-09-04 | Alexander Blair Wilson | EXEC VP, CLO & CORP SECRETARY | A | +180,110 | — |
| 2024-09-04 | Jennifer Sy | PRINCIPAL ACCOUNTING OFFICER | A | +18,010 | — |
| 2024-09-04 | Marc Forth | CHIEF EXECTUIVE OFFICER | A | +470,692 | — |
| 2024-09-04 | Eric G Carter | Director | A | +36,021 | — |
| 2024-09-04 | Robert J Palmisano | Director | A | +36,021 | — |
| 2024-09-04 | Chad Oh | CHIEF MEDICAL OFFICER | A | +192,117 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Timothy P Lynch | 10%+ Owner | 6,500,000 | $1.18M |
| Robert E. Bancroft | PRESIDENT & CEO | 3,177,103 | $577.60K |
| Alexander Blair Wilson | CLO, CSO, and Corp Secretary | 2,183,005 | $396.87K |
| Marc Forth | CHIEF EXECTUIVE OFFICER | 973,231 | $176.93K |
| Chad Oh | CHIEF MEDICAL OFFICER | 866,564 | $157.54K |
| John Bencich | CHIEF FINANCIAL OFFICER | 754,717 | $137.21K |
| Jennifer Sy | PRINCIPAL ACCOUNTING OFFICER | 575,251 | $104.58K |
| Jost Fischer | Director | 489,469 | $88.99K |
| Robert J Palmisano | Director | 290,163 | $52.75K |
| Shelley B Thunen | Director | 258,705 | $47.03K |
| Eric G Carter | Director | 258,705 | $47.03K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AEON quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.